Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27565285 | 0.80 | CYP3A4 (0.39) | CYP3A4CYP2D6CYP2C19ALDH1A1MAPT | |
| SCHEMBL3552768 | 0.78 | — | — | |
| SCHEMBL21217021 | 0.78 | CXCR4 (0.34) | CYP2D6TDP1MEN1KMT2A | |
| SCHEMBL23869469 | 0.78 | CYP3A4 (0.38) | CYP3A4CYP2D6CYP2C19ALDH1A1MAPT | |
| SCHEMBL21540021 | 0.78 | CYP3A4 (0.38) | CYP3A4CYP2D6CYP2C19ALDH1A1MAPT | |
| SCHEMBL21506305 | 0.76 | CYP3A4 (0.37) | CYP3A4CYP2D6CYP2C19ALDH1A1MAPT | |
| SCHEMBL21506034 | 0.76 | CYP3A4 (0.37) | CYP3A4CYP2D6CYP2C19ALDH1A1MAPT | |
| SCHEMBL19407706 | 0.76 | SLC6A2 (0.38) | CYP3A4CYP2D6CYP2C19ALDH1A1MAPT | |
| SCHEMBL21599249 | 0.76 | CYP3A4 (0.37) | CYP3A4CYP2D6CYP2C19ALDH1A1MAPT | |
| SCHEMBL21862178 | 0.76 | CYP3A4 (0.37) | CYP3A4CYP2D6CYP2C19ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | CYP3A4 3314/4885CYP2D6 2252/4885CYP2C19 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.